Global Human Respiratory Syncytial Virus Drugs Market Growth at CAGR of 4.27% - Emergence of New Entrants Likely to Change Market Dynamics - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Human Respiratory Syncytial Virus Drugs Market 2016-2020" report to their offering.

The global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

According to the report, one driver in the market is presence of large patient pool fuels market growth. RSV is the leading cause of lower respiratory tract infections in infants and young children. Each year, 4-5 million children younger than four years of age acquire an RSV infection, and more than 0.12 million are hospitalized annually in the US because of this infection. For example, approximately 25 to 40 out of 100 individuals with RSV have signs or symptoms of pneumonia or bronchiolitis. Five to 20 out of 1,000 require hospitalization.

Key Vendors:

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical

Other Prominent Vendors:

  • Ablynx
  • ADMA Biologics
  • Alnylam Pharmaceuticals
  • Ark Biosciences
  • Aviragen Therapeutics
  • Bavarian Nordic
  • Boehringer Ingelheim
  • Gilead Sciences
  • ImmunoVaccine Technologies
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Medivir
  • Mucosis
  • Mymetics Corporation
  • Novavax
  • Regeneron Pharmaceuticals
  • ReViral
  • Vaxart

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by category of drug

Part 09: Geographical segmentation

Part 10: Market drivers

Part 11: Impact of drivers

Part 12: Market challenges

Part 13: Impact of drivers and challenges

Part 14: Market trends

Part 15: Vendor landscape

Part 16: Key vendor analysis

Part 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/s72648/global_human

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs, Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs, Infectious Diseases Drugs